STROBE Statement—Checklist of items that should be included in reports of ***cross-sectional studies***

	Item No	Recommendation	Page No
Title and abstract	1	(*a*) Indicate the study's design with a commonly used term in the title or the abstract	Page 2 see abstract methods "We conducted a cross-sectional analysis"
		(*b*) Provide in the abstract an informative and balanced summary of what was done and what was found	Page 2 abstract
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	See paragraph 1 and 2 - page 3
Objectives	3	State specific objectives, including any prespecified hypotheses	See paragraph 3 - page 3
Methods			
Study design	4	Present key elements of study design early in the paper	See first paragraph methods page 3
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	See study design in methods section Page 3
Participants	6	(*a*) Give the eligibility criteria, and the sources and methods of selection of participants	All legal outlets operating on November 17th were eligible for participation page 3
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	See sources of data page 4
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	See sources of data page 4
Bias	9	Describe any efforts to address potential sources of bias	See limitations paragraph page 8
Study size	10	Explain how the study size was arrived at	See page 3 for outlets, and page 4 for neighbourhoods. Participants were are all legal cannabis outlets and all neighbourhoods in Canada
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	See Data Analysis page 4 and 5

Statistical methods	12	(*a*) Describe all statistical methods, including those used to control for confounding	See Data Analysis page 4 and 5
		(*b*) Describe any methods used to examine subgroups and interactions	See last paragraph page 4 comparing private and public
		(*c*) Explain how missing data were addressed	Missing data were excluded form analysis page 5
		(*d*) If applicable, describe analytical methods taking account of sampling strategy	NA = no sampling we included all known legal cannabis stores
		(*e*) Describe any sensitivity analyses	See page 5 "we conducted a sensitivity analysis using unadjusted neighbourhood income quintiles from the 2016 census"
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Page 5 first paragraph of results.
		(b) Give reasons for non-participation at each stage	See page 5 "An additional, six stores had been granted a license to operate but had not yet opened and were excluded from analysis."
		(c) Consider use of a flow diagram	NA
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	See table 1 on page 6. Study participants were cannabis stores
		(b) Indicate number of participants with missing data for each variable of interest	See Results first paragraph page 5 "We were not able to find the hours of operation for two stores in Newfoundland & Labrador, these stores were included in the study but excluded from the weekly hours of operation analysis."
Outcome data	15*	Report numbers of outcome events or summary measures	See table 1 on page 6. Outcome events were prespecified measures of cannabis access.
Main results	16	(*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	See table 2 page 7.

		(*b*) Report category boundaries when continuous variables were categorized	Income quintiles from the PCCF+ were predefined by statistics Canada. See Page 4 Neighbourhood Income
		(*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Not relevant in this study design
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	See appendix A page 13
Discussion			
Key results	18	Summarise key results with reference to study objectives	See first paragraph page 7
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	See limitations section page 8
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	See paragraph 2,3 and 4 of the discussion page 8
Generalisability	21	Discuss the generalisability (external validity) of the study results	See conclusions page 9
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	See Funding page 9

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.